[NCI CIRB] LUNGMAP - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer
The purpose of this study is to determine if targeted or immunotherapy treatment will have an effect on specific genes and proteins in the participants tumor.
Non-Small Cell Lung Cancer
1- Pathologically proven Stage IV, or recurrent, Non-Small Cell Lung Cancer
2- Received at least one line of systemic therapy at any stage of disease and have progressed during, or following, their most recent line of therapy OR Current treatment must be for Stage IV, or recurrent disease, and patient must have received at least one dose of current regimen.
3- Must have adequate tumor tissue available per protocol
4- If patient has a known EGFR mutation, ALK gene fusion, ROS1 gene rearrangement or BRAF mutation are deemed not eligible unless they have progressed following all standard of care targeted therapy.
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participants will be followed until sub-study registration, 3 years from registration, or death, whichever comes first.
Knight Information Line - email@example.com or 503-494-1080